文献速递垂体与肾上腺疾病

接受类固醇生成抑制剂治疗患者的临床管理方法

Approach to the Patient Treated with Steroidogenesis Inhibitors.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文针对库欣综合征患者使用类固醇生成抑制剂的临床管理进行综述,涉及酮康唑、左旋酮康唑、美替拉酮和奥西洛司他四种药物。文中讨论了初始剂量、给药方案、疗效监测、单药副作用及联合用药等要点,指出生化控制可在超过50%的病例中实现,但日常管理具有挑战性。

要点

  • 类固醇生成抑制剂可用于手术失败、转移性肿瘤、等待放疗起效或术前严重并发症等多种库欣综合征情境。
  • 生化控制可在超过50%的病例中实现,但需通过多个生物标志物定义正常皮质醇水平。
  • 每种药物均有特定副作用需密切监测,联合用药方案也需关注。

核心结论

  • 类固醇生成抑制剂可用于多种情境下控制库欣综合征的高皮质醇血症,生化控制可在超过50%的病例中实现。

研究设计与样本

  • 本文为「approach to the patient」类型的临床管理综述,聚焦酮康唑、左旋酮康唑、美替拉酮和奥西洛司他四种类固醇生成抑制剂。

主要发现

  • 类固醇生成抑制剂可用于手术未成功或不可行、转移性ACTH或皮质醇分泌肿瘤、等待放疗最大疗效、隐匿性ACTH肿瘤所致严重高皮质醇血症的快速治疗、以及严重合并症患者的术前治疗。
  • 采用剂量滴定或阻断替代方案时,定义正常皮质醇水平通常困难,需要测量多个生物标志物。
  • 每种药物均有自身副作用,必须密切监测。

关键数值与推荐

  • 生化控制可在超过50%的病例中实现。

临床怎么用

  • 内分泌科医生应掌握四种类固醇生成抑制剂的初始剂量、给药方案、疗效监测和单药副作用管理,并考虑联合用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Steroidogenesis inhibitors can be given to control the hypercortisolism of Cushing's syndrome in various situations: when surgery has been unsuccessful or not possible; in metastatic adrenocorticotropin hormone (ACTH) or cortisol-secreting tumors; when waiting for the maximal efficacy of radiation techniques; for rapid treatment of severe hypercortisolism in patients with occult ACTH-producing tumors; or as a presurgical treatment in patients with severe comorbidities. Whilst biochemical "control" can be achieved in more than 50% of cases, daily management of such drugs can be challenging. Indeed, with a "dose-titration" or a "block and replace" approach, defining eucortisolism is usually difficult, requiring the measurement of several biological markers. Moreover, each drug has its own side effects, which must be monitored closely. The aim of this "approach to the patient" is to shed light on the management of hypercortisolism with 4 steroidogenesis inhibitors (ketoconazole, levoketoconazole, metyrapone, osilodrostat) to help endocrinologists dealing with patients with Cushing's syndrome. Various points will be discussed, such as initial dose of treatment, dose schedule, monitoring of efficacy, and side effects of monotherapy. The combination of steroidogenesis inhibitors will also be discussed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Castinetti F, Nieman LK, Reincke M, et al. Approach to the Patient Treated with Steroidogenesis Inhibitors. J Clin Endocrinol Metab. 2021. PMID: 33675650. doi:10.1210/clinem/dgab122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。